| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 |
Poly Medicure
2,526.80
-148.00
(-5.53%)
There are new updates from the company1 day ago
Show All
Market Cap
25,602.98 Cr
EPS
26.92
PE Ratio
79.99
Dividend Yield
0.13 %
Industry
Healthcare52 Week High
3,357.80
52 Week Low
1,570.00
PB Ratio
9.79
Debt to Equity
0.12
Sector
Medical Equipment
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Poly Medicure Reports Strong Q4 Results and Dividend Announcement2 days ago
Poly Medicure has reported its Q4 consolidated net profit at 918.3 million rupees, up from 684 million rupees year-over-year and 852.3 million rupees quarter-over-quarter. The company's Q4 revenue increased to 4.4 billion rupees from 3.7 billion rupees in the previous year. Additionally, Poly Medicure has recommended a dividend of 3.50 rupees per equity share.
Poly Medicure Reports Strong Q4 Results and Announces Dividend2 days ago
Poly Medicure has reported impressive Q4 financial results, with revenue increasing to 4.4 billion rupees from 3.7 billion year-over-year. The company's EBITDA rose to 1.19 billion rupees, up from 964.6 million, with an improved EBITDA margin of 27.1%. Consolidated net profit for Q4 reached 918.3 million rupees, up from 684 million year-over-year and 852.3 million quarter-over-quarter. Additionally, the company has recommended a dividend of 3.50 rupees per equity share.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,526.80 | #1 25,602.98 | #7 79.99 | #1 1,434.50 | #4 24.59 | #1 258 | #2 34.21 | 53.52 | |
370.60 | 1,971.82 | 67.21 | 307.90 | -0.45 | 43 | -46.46 | 54.23 | |
457.10 | 548.66 | 30.98 | 59.30 | 30.58 | 16 | 25.00 | 41.82 | |
242.45 | 242.45 | 280.00 | 102.40 | -13.51 | -2 | #1 159.52 | 56.13 | |
209.00 | 111.78 | 72.78 | 17.80 | #1 136.23 | 2 | -98.33 | 42.59 | |
97.50 | 101.77 | #1 10.71 | 109.90 | -1.43 | 10 | - | 41.91 | |
129.95 | 47.41 | 49.19 | 51.30 | -2.84 | 1 | -400.00 | 56.33 | |
125.00 | 41.30 | 82.78 | 14.00 | 27.27 | 1 | - | 84.07 | |
46.00 | 39.80 | 20.81 | 32.30 | 14.13 | 3 | 0.50 | 50.88 | |
65.10 | 32.82 | - | 89.80 | 17.54 | -3 | -35.71 | 40.58 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
24.59 %
Net Income Growth
44.06 %
Cash Flow Change
39.27 %
ROE
21.68 %
ROCE
22.93 %
EBITDA Margin (Avg.)
11.00 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 749 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 193 | 171 | 227 | 293 | 351 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 139 | 87 | 63 | 42 | 37 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -107 | -436 | -85 | -179 | -241 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 128 | 119 | 124 | 191 | 266 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 May 2025 |  Quarterly Result Announcement | NA | 06 May 2025 | 2,587.85 | 2,584.60 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,445.25 | 2,433.90 |
| 28 Oct 2024 | Quarterly Result Announcement | NA | 28 Oct 2024 | 2,450.95 | 2,514.10 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,498.45 | 2,318.00 |
| 20 Sept 2024 |  Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,654.70 | 2,462.65 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 977.25 | 1,413.65 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 715.55 | 933.00 |
| 17 Sept 2021 | Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,133.15 | 955.00 |
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Change in Management2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Resignation of Director2 days ago
2 days agoRe-Appointment Of Internal Auditors
Appointment Of Secretarial Auditor2 days ago
2 days agoAudited Standalone & Consolidated Financial Results For The Quarter And Year Ended 31.03.20252 days ago
2 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Of The Company In Compliance Of Regulation 30 And 33 Of SEBI (LODR) Regulations 2015
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
6 days agoBoard Meeting Intimation for Intimation Of Board Meeting To Be Held On 06Th May 2025.10 days ago
10 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Intimation Of Receiving The Medical Device Regulation (MDR) Certification In Europe For 54 ProductsMar 11, 2025
Mar 11, 2025Statement Of Deviation(S) Or Variation(S) For The Quarter Ended 31St December 2024.Feb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 05, 2025
Feb 05, 2025Integrated Filing (Financial)Feb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2025
Feb 03, 2025Unaudited Financial Results (Standalone & Consolidated) For The Third Quarter And Nine Months Ended On 31St December 2024Feb 03, 2025
Feb 03, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Today I.E. 03Rd February 2025Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Jan 29, 2025Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 03Rd February 2025Jan 27, 2025
Jan 27, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJan 25, 2025
Jan 25, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2025
Jan 14, 2025Announcement under Regulation 30 (LODR)-Joint VentureJan 10, 2025
Jan 10, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 02, 2024
Dec 02, 2024Statement Of Deviation(S) Or Variation(S), If Any, Of Utilization Of Proceeds Received From Qualified Institutions Placement (QIP) Under Regulation 32 Of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015.Nov 13, 2024
Nov 13, 2024Monitoring Agency Report For The Quarter Ended 30Th September, 2024 - QIP Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015Nov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 28, 2024
Oct 28, 2024Announcement under Regulation 30 (LODR)-Change in ManagementOct 28, 2024
Oct 28, 2024Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.Oct 28, 2024
Oct 28, 2024Board Meeting Outcome for Outcome Of The Board Meeting Of The Company In Compliance Of Regulation 30 And 33 Of SEBI (LODR) Regulations, 2015Oct 28, 2024
Oct 28, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 24, 2024
Oct 24, 2024Board Meeting Intimation for Board Meeting Intimation Scheduled To Be Held On 28Th October, 2024.Oct 19, 2024
Oct 19, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 15, 2024
Oct 15, 2024Closure of Trading WindowSep 30, 2024
Sep 30, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 28, 2024
Sep 28, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateSep 26, 2024
Sep 26, 2024Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2024
Sep 26, 2024Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2024
Sep 26, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2024
Sep 06, 2024Business Responsibility and Sustainability Reporting (BRSR)Sep 04, 2024
Sep 04, 2024Intimation Of Book Closure For The Payment Of Dividend For The Financial Year 2023-24Sep 04, 2024
Sep 04, 2024Technical Indicators
RSI(14)
Neutral 62.53
ATR(14)
Less Volatile 132.18
STOCH(9,6)
Neutral 67.43
STOCH RSI(14)
Neutral 41.21
MACD(12,26)
Bullish 22.54
ADX(14)
Strong Trend 31.02
UO(9)
Bearish 62.18
ROC(12)
Uptrend But Slowing Down 9.08
WillR(14)
Neutral -46.71
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and Italy, with seven in India, one in China through a wholly-owned subsidiary, one in Egypt through an associate, and one in Italy through a step-down subsidiary. The company exports to over 110 countries through a network of more than 220 distributors. Poly Medicure's facilities are accredited with international quality certifications, including ISO 9001:2015 and EN ISO 13485:2016. The company has an R&D center in Faridabad, Haryana, approved by DSIR, focusing on developing new products and improving existing processes. Poly Medicure holds over 375 patents for its products in various therapeutic areas.
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
